{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:45:06Z","timestamp":1791499506241,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T00:00:00Z","timestamp":1338163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To compare mycological and complete cures of terbinafine continuous and intermittent regimens in the treatment of toenail onychomycosis.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> The PubMed database was searched using the terms \u201cterbinafine\u201d, \u201conychomycosis\u201d, \u201ccontinuous\u201d and \u201cpulse(d)\u201d or \u201cintermittent\u201d. The inclusion criteria were head\u2010to\u2010head comparison of terbinafine pulse and continuous regimens for dermatophyte toenail infections. Risk ratios were calculated for intention\u2010to\u2010treat and evaluable patient analyses, when possible. Pooled estimates for total and subgroup analyses were calculated using a random effect model, Mantel\u2010Haenszel method and their probabilities were calculated with z\u2010statistics.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Nine studies from eight publications were included. Two continuous regimens and four intermittent regimens were investigated. A pooled risk ratio of 0.87 was obtained for intention\u2010to\u2010treat (95% CI: 0.79\u20130.96, <jats:italic>P\u2003<\/jats:italic>=\u20030.004, <jats:italic>n<\/jats:italic>\u2003=\u20036) and evaluable patient (95% CI: 0.80\u20130.96, <jats:italic>P\u2003<\/jats:italic>=\u20030.003, <jats:italic>n<\/jats:italic>\u2003=\u20038) analyses of mycological cure, favouring continuous terbinafine. For complete cure, pooled risk ratios of 0.97 (95% CI: 0.77\u20131.23, <jats:italic>P\u2003<\/jats:italic>=\u20030.82, <jats:italic>n<\/jats:italic>\u2003=\u20037) for intention\u2010to\u2010treat and 0.93 (95% CI: 0.76\u20131.13, <jats:italic>P\u2003<\/jats:italic>=\u20030.44, <jats:italic>n<\/jats:italic>\u2003=\u20039) for evaluable patient analyses showed equality of the two regimens. The pulse regimen that demonstrated consistently comparable results to the continuous terbinafine regimen was two pulses of terbinafine 250\u2003mg\/day for 4\u2003weeks on\/4\u2003weeks off.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Meta\u2010analysis of published studies of toenail onychomycosis showed that a continuous terbinafine regimen is generally significantly superior to a pulsed terbinafine regimen for mycological cure. In contrast, some pulse terbinafine regimens were as effective as continuous terbinafine regimens for complete cure.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2012.04584.x","type":"journal-article","created":{"date-parts":[[2012,5,28]],"date-time":"2012-05-28T08:03:29Z","timestamp":1338192209000},"page":"267-272","source":"Crossref","is-referenced-by-count":54,"title":["Terbinafine in the treatment of dermatophyte toenail onychomycosis: a meta\u2010analysis of efficacy for continuous and intermittent regimens"],"prefix":"10.1111","volume":"27","author":[{"given":"A.K.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tavakkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,5,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1972.01620050069017"},{"key":"e_1_2_5_3_2","first-page":"889","article-title":"Technics of nail biopsy","volume":"114","author":"Andre J","year":"1987","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107754"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.415"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.109069"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb00005.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1997.00349.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70420-4"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701657187"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7015.1277"},{"key":"e_1_2_5_12_2","first-page":"302","article-title":"The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence","volume":"4","author":"Gupta AK","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(09)80305-8"},{"key":"e_1_2_5_14_2","unstructured":"Lamisil. (terbinafine hydrochloride tablets) Prescribing information. [WWW document].Novartis Pharmaceuticals Corporation East Hanover NJ USA URLhttp:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/Lamisil_tablets.pdf[accessed on 20 December 2011]"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.7547\/0960038"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05728.x"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5154.62746"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10227-002-0139-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)80057-0"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630410018076"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.055"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500504713"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.03036.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.1996.tb04009.x"},{"key":"e_1_2_5_25_2","first-page":"1253","article-title":"Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial","volume":"137","author":"Warshaw EM","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_5_26_2","first-page":"481","article-title":"Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator\u2010blinded study","volume":"4","author":"Gupta AK","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.11.027"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.7547\/87507315-93-5-373"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.03.021"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1099\/00221287-16-3-642"},{"issue":"60","key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2133.2001.00047.x","article-title":"The rationale for combination therapy","volume":"145","author":"Evans EG","year":"2001","journal-title":"Br J Dermatol"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.44.1.98-101.2006"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycres.2006.08.006"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn245"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-011-9433-7"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.08.007"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46474-0"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)91807-8"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01138.x"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1995.tb01353.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2012.04584.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2012.04584.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:16:42Z","timestamp":1697343402000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2012.04584.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,28]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1111\/j.1468-3083.2012.04584.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04584.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,28]]}}}